Literature DB >> 16126329

Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma.

Gaëlle Fromont1, Morgan Rouprêt, Najla Amira, Mathilde Sibony, Guy Vallancien, Pierre Validire, Olivier Cussenot.   

Abstract

OBJECTIVES: Invasive upper urinary tract transitional cell carcinoma (UUT-TCC) has a poor prognosis (survival <50% at 5 years), and tumor stage and grade often fail to predict outcome. Our purpose was to establish whether the expression of Ki67, p53, p27, E-cadherin, survivin or MSH2 can provide prognostic information in UUT-TCC.
METHODS: The following data from the files of 62 patients treated for UUT-TCC over 12 years were collated: age at diagnosis, prior history of cancer, tobacco consumption, tumor stage (including surgical margins) and grade, and disease progression. Immunohistochemistry (IHC) for Ki67, p53, p27, E-cadherin, survivin and MSH2 was performed on tissue microarray sections from tumor tissue.
RESULTS: Overall, 31 patients died with metastasis from UUT-TCC. Mean survival was 20+/-16 months (range 2-83). In a univariate analysis, advanced age (>68 years), high stage, and loss of E-cadherin and high Ki67 expression were associated with a poor prognosis and disease recurrence. In a multivariate analysis, the independent factors of prognosis and recurrence were E-cadherin (p=0.001; p=0.004), age (p=0.022; p=0.008), and high stage (p=0.023; p=0.008).
CONCLUSIONS: E-cadherin is a useful independent prognostic factor in UUT-TCC, for use in addition to age and tumor stage. It is of particular interest to predict recurrence in patients with low grade non-invasive tumors. Ki67 expression is informative but less significant. Survivin, p53, p27 and MSH2 have no prognostic value.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16126329     DOI: 10.1016/j.eururo.2005.07.005

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  25 in total

1.  Divergent squamous differentiation in upper urothelial carcinoma-comparative clinicopathological and molecular study.

Authors:  Ljubinka Jankovic Velickovic; Zana Dolicanin; Takanori Hattori; Ivana Pesic; Biljana Djordjevic; Mariola Stojanovic; Jablan Stankovic; Milan Visnic; Vladisav Stefanovic
Journal:  Pathol Oncol Res       Date:  2010-12-02       Impact factor: 3.201

Review 2.  Expression of p53 in upper urinary tract urothelial carcinoma.

Authors:  Stephen Mitchell; Erik Mayer; Anup Patel
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

3.  Upper urinary tract urothelial carcinoma: what have we learned in the last 4 years?

Authors:  Mesut Remzi; Shahrokh Shariat; Wilhelm Huebner; Harun Fajkovic; Christian Seitz
Journal:  Ther Adv Urol       Date:  2011-04

Review 4.  Prognostic factors for upper urinary tract urothelial carcinoma.

Authors:  Thomas F Chromecki; Karim Bensalah; Mesut Remzi; Grégory Verhoest; Eugene K Cha; Douglas S Scherr; Giacomo Novara; Pierre I Karakiewicz; Shahrokh F Shariat
Journal:  Nat Rev Urol       Date:  2011-07-05       Impact factor: 14.432

Review 5.  Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours.

Authors:  David R Yates; James W F Catto
Journal:  World J Urol       Date:  2012-09-18       Impact factor: 4.226

6.  Increased nucleophosmin expression is a strong predictor of recurrence and prognosis in patients with N0M0 upper tract urothelial carcinoma undergoing radical nephroureterectomy.

Authors:  Harutake Sawazaki; Keiichi Ito; Takako Asano; Kenji Kuroda; Akinori Sato; Junichi Asakuma; Akio Horiguchi; Kenji Seguchi; Tomohiko Asano
Journal:  World J Urol       Date:  2016-11-24       Impact factor: 4.226

7.  Risk stratification model, including preoperative serum C-reactive protein and estimated glomerular filtration rate levels, in patients with upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy.

Authors:  Shuichi Morizane; Tetsuya Yumioka; Noriya Yamaguchi; Toshihiko Masago; Masashi Honda; Takehiro Sejima; Atsushi Takenaka
Journal:  Int Urol Nephrol       Date:  2015-06-24       Impact factor: 2.370

8.  Snail immunohistochemical overexpression correlates to recurrence risk in non-muscle invasive bladder cancer: results from a longitudinal cohort study.

Authors:  Raffaella Santi; Tommaso Cai; Stefania Nobili; Ilaria Camilla Galli; Andrea Amorosi; Eva Comperat; Gabriella Nesi
Journal:  Virchows Arch       Date:  2018-03-10       Impact factor: 4.064

Review 9.  Predictive factors of recurrence and survival of upper tract urothelial carcinomas.

Authors:  Grégory Verhoest; Shahrokh F Shariat; Thomas F Chromecki; Jay D Raman; Vitaly Margulis; Giacomo Novara; Christian Seitz; Mesut Remzi; Morgan Rouprêt; Douglas S Scherr; Karim Bensalah
Journal:  World J Urol       Date:  2011-06-17       Impact factor: 4.226

10.  A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.

Authors:  Maha Hussain; Stephanie Daignault; Neeraj Agarwal; Petros D Grivas; Arlene O Siefker-Radtke; Igor Puzanov; Gary R MacVicar; Ellis Glenn Levine; Sandy Srinivas; Przemyslaw Twardowski; Mario A Eisenberger; David I Quinn; Ulka N Vaishampayan; Evan Y Yu; Scott Dawsey; Kathleen C Day; Mark L Day; Mahmoud Al-Hawary; David C Smith
Journal:  Cancer       Date:  2014-05-06       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.